Evidence map›Paper›PMID 31411090›Full record

SynthesisJournal of the American Heart Association2019

Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis.

Xin-Lin Zhang, Rong-Fang Lan, Xiao-Wen Zhang, Wei Xu, Lian Wang, Li-Na Kang, Biao Xu

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Journal of the American Heart Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xin-Lin ZhangDepartment of Cardiology Affiliated Drum Tower Hospital Nanjing University School of Medicine Nanjing China.
Rong-Fang LanDepartment of Cardiology Affiliated Drum Tower Hospital Nanjing University School of Medicine Nanjing China.
Xiao-Wen ZhangDepartment of Endocrinology Affiliated Drum Tower Hospital Nanjing University School of Medicine Nanjing China.
Wei XuDepartment of Cardiology Affiliated Drum Tower Hospital Nanjing University School of Medicine Nanjing China.
Lian WangDepartment of Cardiology Affiliated Drum Tower Hospital Nanjing University School of Medicine Nanjing China.
Li-Na KangDepartment of Cardiology Affiliated Drum Tower Hospital Nanjing University School of Medicine Nanjing China.
Biao XuDepartment of Cardiology Affiliated Drum Tower Hospital Nanjing University School of Medicine Nanjing China.
Nanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Several lipid-lowering therapies reduce CRP (C-reactive protein) independently of LDL-C (low-density lipoprotein cholesterol) reduction, but the association between CRP parameters and benefits from more-intensive LDL-C lowering is inconclusive. We aimed to determine whether the benefits of more- versus less-intensive LDL-C lowering on cardiovascular events related to baseline, achieved, or magnitude of reduction in CRP concentrations. Methods and Results PubMed, EMBASE, and Cochrane were searched through July 2, 2018. We included randomized controlled cardiovascular outcome trials of LDL-C lowering with statins or ezetimibe. Two reviewers independently extracted study data and rated study quality. Data were analyzed using meta-analysis and metaregression analysis. Rate ratios of mortality and cardiovascular outcomes associated with baseline, achieved, and magnitude reduction of CRP concentration were calculated. Twenty-four trials were included, with 171 250 patients randomly assigned to more- or less-intensive LDL-C-lowering treatments. Median follow-up duration was 4.2 years. More-intensive LDL-C lowering resulted in a significant reduction in incidences of all outcomes. Compared with less-intensive LDL-C lowering, more-intensive LDL-C lowering was associated with less reductions in myocardial infarction with a higher baseline CRP concentration (change in rate ratios per 1-mg/L increase in log-transformed CRP, 1.12 [95% CI, 1.04-1.22; P=0.007]), but not other outcomes. Similar risk reductions occurred for more- versus less-intensive LDL-C-lowering therapy regardless of the magnitude of CRP reduction or the achieved CRP level for all outcomes. Conclusions Baseline CRP concentrations might be associated with the benefits of LDL-C lowering on myocardial infarction, but no other outcomes, whereas the achieved and magnitude of reduction in CRP did not seem to have an important association.

Indexed as

Anticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLC-Reactive ProteinEzetimibeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaMyocardial InfarctionMyocardial RevascularizationStrokeTreatment OutcomeAnticholesteremic AgentsCholesterol, LDLC-Reactive ProteinEzetimibeHydroxymethylglutaryl-CoA Reductase Inhibitorscardiovascular outcomesC‐reactive proteinLDL‐cholesterollipid loweringmeta‐analysisrandomized controlled trials

Identifiers

PMID31411090
PMCPMC6759897
OpenAlexW2969108661

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.